News
SIEN
--
0.00%
--
Sientra Says AlloX2 Tissue Expander Provided Efficient Seroma Management in Retrospective Study
MT Newswires · 08/25 12:30
Sientra Highlights Study From Stanford University's School Of Medicine
 Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgery, today announced that a recent independent study out of Stanford
Benzinga · 08/25 12:05
New Study Confirms Sientra’s AlloX2’s Unique Value in Managing Seroma and Infection Post Reconstruction Procedures
SANTA BARBARA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgery, today announced that a recent independent study out of Stanford University...
GlobeNewswire · 08/25 12:00
Soleus Capital Management, L.P. Buys BioAtla Inc, NeuroPace Inc, C4 Therapeutics Inc, Sells ...
GuruFocus News · 08/23 21:38
Sientra (SIEN) Reports Q2 Loss, Lags Revenue Estimates
Sientra (SIEN) delivered earnings and revenue surprises of 4.35% and -0.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/10 21:45
Sientra: Q2 Earnings Insights
Shares of Sientra (NASDAQ:SIEN) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 52.94% year over year to ($0.32), which missed the estimate of ($0.22).
Benzinga · 08/10 20:32
Sientra EPS misses by $0.13, misses on revenue. updates guidance
Sientra (NASDAQ:SIEN): Q2 GAAP EPS of -$0.35 misses by $0.13. Revenue of $20.1M (+62.1% Y/Y) misses by $0.58M. Shares -4%. Press Release Updated full year 2021 guidance for revenues expected
Seekingalpha · 08/10 20:28
BRIEF-Sientra Reports Record Breast Products Revenue For Q2 2021, Raises Revenue Guidance For FY2021
reuters.com · 08/10 20:27
Sientra Q2 EPS $(0.35) Misses $(0.22) Estimate, Sales $20.10M Miss $20.68M Estimate
Sientra (NASDAQ:SIEN) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.22) by 59.09 percent. This is a 48.53 percent increase over losses of $(0.68) per share from the
Benzinga · 08/10 20:17
Sientra Q2 Loss Narrows as Revenue Rises; Lifts FY2021 Guidance
MT Newswires · 08/10 16:39
-- Earnings Flash (SIEN) SIENTRA Posts Q2 Revenue $20.1M, vs. Street Est of $20.7M
MT Newswires · 08/10 16:09
Earnings Reaction History: SIENTRA INC, 55.6% Follow-Through Indicator, 15.8% Sensitive
MT Newswires · 08/10 12:33
Do Institutions Own Sientra, Inc. (NASDAQ:SIEN) Shares?
Every investor in Sientra, Inc. ( NASDAQ:SIEN ) should be aware of the most powerful shareholder groups. Institutions...
Simply Wall St. · 08/10 09:39
Sientra (SIEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks.com · 08/03 19:01
Eko Appoints Renee Gaeta as Chief Financial Officer
Gaeta, a seasoned medical technology executive joins the company as it continues its product and healthcare market expansion Eko Appoints Renee Gaeta as Chief Financial Officer Renee Gaeta, a seasoned medical technology executive joins the company as it co...
GlobeNewswire · 08/02 12:00
Sientra to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
Sientra, Inc. (NASDAQ: SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Tuesday, Augus...
GlobeNewswire · 07/27 20:01
Aesthetic Devices Market Size 2021 Explosive Factors of Revenue By Progression Status, Emerging Demands, Recent Trends, Business Opportunity, Share and Forecast To 2027
The scope of the report includes a detailed study of Global Aesthetic Devices Market with the reasons given for variations in the growth of the industry in certain regions.
Heraldkeepers · 07/27 18:15
BRIEF-Sientra Inc - On July 16, Board Approved An Increase In Size Of Board From 7 Directors To 9 Directors
reuters.com · 07/22 21:26
Hedge Funds Have Never Been This Bullish On Sientra Inc (SIEN)
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of March 31st. The ...
Insider Monkey · 07/20 14:29
BRIEF-Sientra Announces Appointment Of Chief Financial Officer
reuters.com · 07/12 12:18
Webull provides a variety of real-time SIEN stock news. You can receive the latest news about Sientra through multiple platforms. This information may help you make smarter investment decisions.
About SIEN
Sientra, Inc. is a medical aesthetics company. The Company's primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 400 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. Implant Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders for reconstruction procedures predominantly to hospitals and surgery centers, and its BIOCORNEUM scar management products to plastic surgeons, dermatologists and other specialties. The Company's brands also include OPUS, Luxe, Curve, AlloX2, Dermaspan and Softspan.